Dtsch Med Wochenschr 2012; 137(22): 1188-1191
DOI: 10.1055/s-0032-1305004
Rheumatologie | Commentary
Rheumatologie
© Georg Thieme Verlag KG Stuttgart · New York

Vaskulitis

Update 2012Vasculitiswhat’s new?
B. Hellmich
1   Kreiskliniken Esslingen gGmbH, Klinik Plochingen
,
M. Fleck
2   Klinik und Poliklinik für Innere Medizin I, Universitätsklinikum Regensburg
3   Klinik für Rheumatologie/ Klinische Immunologie, Asklepios-Klinikum Bad Abbach
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
22. Mai 2012 (online)

 
  • Literatur

  • 1 Clowse ME, Copland SC, Hsieh TC et al. Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) 2011; 63: 1777-1781
  • 2 Dasgupta B, Cimmino MA, Kremers HM et al. 2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 2012; 64: 943-954
  • 3 de Menthon M, Cohen P, Pagnoux C et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. Clin Exp Rheumatol 2011; 29 Suppl. (Suppl. 64) S63-S71
  • 4 De Vita S, Quartuccio L, Isola M et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64: 843-853
  • 5 Falk RJ, Gross WL, Guillevin L et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis 2011; 70: 704
  • 6 Flossmann O, Berden A, de Groot K et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70: 488-494
  • 7 Harper L, Morgan MD, Walsh M et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2011; Nov 29. [Epub ahead of print]
  • 8 Holle JU, Dubrau C, Herlyn K et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 2011; Oct 21. [Epub ahead of print]
  • 9 Holle JU, Gross WL, Latza U et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 2011; 63: 257-266
  • 10 LeGuenno G, Mahr A, Pagnoux C. French Vasculitis Study Group et al. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum 2011; 63: 1435-1445
  • 11 Moosig F, Gross WL, Herrmann K et al. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 2011; 155: 341-343
  • 12 Restuccia G, Cavazza A, Boiardi L et al. Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery. Arthritis Rheum 2012; 64: 549-556
  • 13 Roubaud-Baudron C, Pagnoux C, Méaux-Ruault N et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 2011; Nov 15. [Epub ahead of print]
  • 14 Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64: 835-842
  • 15 Spiera R, Westhovens R. Provisional diagnostic criteria for polymyalgia rheumatica: Moving beyond clinical intuition?. Arthritis Rheum 2012; 64: 955-957